Skip to main content
. 2020 May 27;87(6):1139–1147. doi: 10.1093/neuros/nyaa201

TABLE 3.

Quality of Life of Patients (N = 8) Before and After Treatment

Baselinea 6-mo follow-upb 1-yr follow-up
PDQ-8
 Total 9.6 ± 5.4 4.1 ± 3.7a 6.5 ± 4.5
 Mobility 1.5 ± 0.9 1.0 ± 1.4 1.1 ± 1.1
 Activity of daily living 1.5 ± 0.8 0.6 ± 1.1a 0.8 ± 0.9
 Emotional well-being 1.0 ± 1.1 0.3 ± 0.5 0.4 ± 0.7
 Stigma 0.9 ± 1.1 0 ± 0 0.5 ± 0.8
 Social support 0.6 ± 0.9 0 ± 0 0.8 ± 0.7b
 Cognitions 1.4 ± 1.1 0.3 ± 0.5 0.4 ± 0.7a
 Communications 1.0 ± 1.2 0.4 ± 1.1 1.8 ± 1.0a
 Bodily discomfort 1.8 ± 1.5 1.6 ± 1.0 0.9 ± 1.1
EQ-5D-5L
 Global health status 72.5 ± 17.3 72.1 ± 20.4 83.1 ± 11.9
 Mobility 1.0 ± 0.8 0.6 ± 0.5 0.6 ± 0.7
 Self-care 1.3 ± 1.3 0.3 ± 0.5 0.4 ± 0.7a
 Activities of daily living 1.3 ± 1.6 0.6 ± 0.8 0.6 ± 0.9
 Pain or discomfort 0.9 ± 0.8 0.4 ± 0.5 1.1 ± 1.0
 Anxiety or depression 1.3 ± 1.0 0.1 ± 0.4a 0.4 ± 0.5
UPDRS-I
 Total 15.1 ± 7.6 8.9 ± 4.4a 10.3 ± 6.9a
 Mood status 2.8 ± 3.1 0.4 ± 0.5a 1.4 ± 1.3b
 Other nonmotor functions 12.4 ± 4.9 8.4 ± 4.2a 8.9 ± 5.7a
UPDRS-II
 Total 16.4 ± 8.7 10.9 ± 5.1 10.5 ± 8.4a
 Fine motor functions 5.6 ± 4.1 5.6 ± 3.2 4.8 ± 4.0
 Tremor and eating task 2.6 ± 1.8 1.0 ± 1.2a 1.1 ± 1.4a
 Complex motor functions 8.1 ± 4.9 4.3 ± 2.9 4.6 ± 3.8a
BMI (kg/m²) 26.9 ± 3.7 n/a 26.9 ± 3.8

BMI, body mass index; EQ-5D-5 L, 5-Level EuroQol-5 Dimensions; n/a, not applicable; PDQ, Parkinson Disease Questionnaire; UPDRS, Unified Parkinson Disease Rating Scale.

a,bThe letters a and b indicate a significant difference (P < .05) between 2 time points (Wilcoxon signed-ranks tests).

Values are presented as mean ± SD.